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The non-canonical Wnt/planar cell polarity (Wnt/PCP) pathway plays a crucial role in
embryonic development. Recent work has linked defects of this pathway to breast cancer
aggressiveness and proposed Wnt/PCP signalling as a therapeutic target. Here we show
that the archetypal Wnt/PCP protein VANGL2 is overexpressed in basal breast cancers,
associated with poor prognosis and implicated in tumour growth. We identify the scaffold
p62/SQSTM1 protein as a novel VANGL2-binding partner and show its key role in an
evolutionarily conserved VANGL2–p62/SQSTM1–JNK pathway. This proliferative signalling
cascade is upregulated in breast cancer patients with shorter survival and can be inactivated
in patient-derived xenograft cells by inhibition of the JNK pathway or by disruption of the
VANGL2–p62/SQSTM1 interaction. VANGL2–JNK signalling is thus a potential target for
breast cancer therapy.
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reast cancer is a molecularly heterogeneous disease that
comprises five major subtypes (luminal A and B, ERBB2,
basal and normal-like) with different clinical characteristics
and prognosis1. Basal breast cancer is a very aggressive
subtype with high propensity for metastasis formation and poor
prognosis2. Owing to the lack of hormone receptor (oestrogen
receptor (ER) and progesterone receptor (PR)) and ERBB2
expression, patients cannot benefit from hormone therapy
or targeted therapy, the only remaining available systemic
treatment being standard chemotherapy. Despite new
therapeutic approaches such as the optimization of common
cytotoxic agents and the testing of novel drugs such as epidermal
growth factor receptor (EGFR) and poly-ADP-ribose-
polymerase-1 inhibitors, there is still a strong need for novel
therapeutic targets for this aggressive breast cancer subtype.
Breast cancer cells commonly reactivate embryonic
developmental pathways to promote tumour growth and
dissemination. Among these pathways, Wnt signalling plays a
crucial role through its involvement in many aspects of the
disease, including self-renewal of cancer stem cells, tumour
initiation, metastatic development and drug resistance3. The
Wnt pathway is subdivided into b-catenin-dependent and
b-catenin-independent (also called non-canonical) cascades.
The latter can be further subdivided into Wnt/calcium and
Wnt/planar cell polarity (Wnt/PCP) pathways. The precise
mechanism by which Wnt ligands trigger b-catenin-dependent
or b-catenin-independent Wnt signalling pathways remains
unclear, but probably involves distinct Wnt receptors3.
Hyperactivation of b-catenin-dependent Wnt signalling has
been demonstrated in breast cancer in the late 90s and
correlates with poor prognosis4–6. Several components of the
Wnt/PCP pathway regulate cancer cell motility and invasion,
although their involvement in tumorigenesis has long remained
elusive. Recent studies have linked upregulation of Wnt/PCP
signalling to the development and dissemination of breast cancer7
and to poor clinical outcome8,9. Increased levels of VANGL1–
SCRIB and WNT5A/B–FRIZZLED2 correlate with high risk of
patient relapse and with progression of late-stage metastatic
cancers, respectively. Because targeting this pathway could benefit
breast cancer patients9, unravelling Wnt/PCP signalling may
provide new opportunities for therapeutic intervention.
Wnt/PCP signalling is the least well-characterized Wnt
pathway. It regulates biological processes crucial for embryonic
development and tissue homeostasis in adults10,11. The
importance of Wnt/PCP genes such as VANGL2 in
developmental processes is best reflected by their involvement
in human genetic diseases such as neural tube closure defects12.
Wnt/PCP signalling, which was initially described in the fruit fly
Drosophila melanogaster, serves to polarize many epithelial
tissues and organizes morphogenetic events in invertebrates and
vertebrates10,11. In addition to Wnt, a set of core Wnt/PCP genes
in Drosophila including frizzled, van gogh (homologue of human
VANGL1 and VANGL2), scribble, prickle, dishevelled, flamingo,
fat, dachsous and diego constitute a signalling cassette conserved
in vertebrates. In invertebrates as well as in vertebrates, the
Wnt/PCP pathway leads to activation of small RHO-like GTPases
RHOA, RAC1 and c-JUN N-terminal Kinase (JNK)3. The
underlying mechanism by which Wnt/PCP signalling activates
JNK remains unclear. In addition to its role in morphogenesis,
JNK is involved in apoptosis, cell proliferation and cell motility,
and can contribute to tumour promotion or inhibition depending
on the cellular and tissue context13.
Here we report the overexpression of the Wnt/PCP core
component VANGL2 in breast cancers with poor prognosis. We
demonstrate the involvement of VANGL2 in tumour growth in
cell culture and mice. We identify p62/sequestosome-1 (hereafter
named p62/SQSTM1) as a novel VANGL2-binding partner in
breast cancer cells. p62/SQSTM1 is an intracellular Phox and
Bem1p (PB1) domain-containing scaffold protein involved in
important processes such as selective autophagy, cell signalling
and induction of epithelial–mesenchymal transition (EMT)14,15.
p62/SQSTM1 has been linked to several diseases such as Paget’s
disease of bone, neurodegenerative diseases, liver disorders and
cancer16. It is overexpressed in breast cancers, including
aggressive basal and ERBB2 subtypes, and involved in many
aspects of oncogenesis17–20. We find that p62/SQSTM1 is
required to recruit and activate JNK in breast cancer cells
through an evolutionarily conserved VANGL2–p62/SQSTM1–
JNK signalling cascade. This proliferative pathway is upregulated
in breast cancer patients with shorter survival and in patient-
derived xenografts (PDXs), and is sensitive to inhibition of
JNK and of the VANGL2–p62/SQSTM1 interaction. These data
describe a non-canonical Wnt/PCP pathway overexpressing
VANGL2 in aggressive breast cancer and identify p62/SQSTM1
as an important player in VANGL2–JNK signalling.
Results
Overexpression of VANGL2 in breast cancer. To address the
role of VANGL2 in breast cancer, we first examined VANGL2
messenger RNA expression in a large data set of 2,687 invasive
breast cancers (Supplementary Table 1). Whole-genome cluster-
ing showed that VANGL2 was part of the ‘basal’ gene cluster that
also includes KRT5/6/17 and CRYAB genes (Fig. 1a). A total of
625 tumours (23%) showed VANGL2 mRNA upregulation
compared with normal breast (NB). The analysis of available
array-comparative genomic hybridization (aCGH) data from 208
samples revealed that half of them show a gain of VANGL2 DNA
copy number, which is statistically correlated with mRNA upre-
gulation (Student’s t-test, Po0.001; Fig. 1b). Histoclinical corre-
lations (Supplementary Table 2) revealed that VANGL2
upregulation is associated with larger tumour size (Fisher’s exact
test, P¼ 0.009), ER-negative (Fisher’s exact test, Po0.001), PR-
negative (Fisher’s exact test, Po0.001) and ERBB2-negative
(Fisher’s exact test, P¼ 0.017) immunohistochemistry (IHC)
status, triple-negative status (Fisher’s exact test, Po0.001) and
basal subtype (Fisher’s exact test, Po0.001; Fig. 1c), and tends to
be associated with higher grade (Fisher’s exact test, P¼ 0.067).
VANGL2 upregulation correlates with poor metastasis-free sur-
vival (MFS) in both univariate (log-rank test, P¼ 0.004; Fig. 1d)
and multivariate (Wald test, P¼ 0.005) analyses (Supplementary
Table 3). IHC analysis for VANGL2 using 2G4 monoclonal
antibody21 showed that the VANGL2 protein is abundant in
epithelial cancer cells of patient tumours compared with
surrounding tissues, suggesting a cell-autonomous activity in
tumours (Fig. 1e). Epithelial expression of VANGL2 was
confirmed in a panel of 35 breast cancer cell lines previously
profiled using DNA microarrays22. VANGL2 expression was
found to be heterogeneous across cell lines and higher in the basal
and mesenchymal cell lines, such as SUM149 and SKBR7, than in
the luminal ones (Supplementary Fig. 1), as observed in the
clinical cancer samples.
VANGL2 is implicated in tumour growth. To assess the
functional importance of VANGL2 in basal breast cancer cells,
VANGL2 protein levels were stably reduced using two short
hairpin RNAs (shVANGL2 seq1 and seq2) in SUM149 (Fig. 2a)
and HCC1806 (Fig. 2b) cells. In both cases, VANGL2 was
efficiently knocked down (490%; Fig. 2a,b, upper panels).
VANGL2-depleted SUM149 (Fig. 2a, lower panel, and
Supplementary Fig. 2) and HCC1806 (Fig. 2b, lower panel) cells
xenografted into NOD/SCID/gc null female mice (NSG) showed
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reduced in vivo tumour growth compared with cells transfected
with shLuc. The reduced tumour growth of VANGL2-depleted
cells was confirmed by in vitro assays. First, as previously shown
in other cell models23, we found that VANGL2 depletion
impaired SUM149-directed cell migration in Boyden chamber
assays (Supplementary Fig. 2). Second, we tested anchorage-
dependent and -independent proliferation and observed that
loss of VANGL2 decreased the proliferation rates of SUM149
(Fig. 2c and Supplementary Fig. 2) and HCC1806 cells (Fig. 2d).
To determine whether overexpression of VANGL2 participates in
tumorigenesis, green fluorescent protein (GFP)-tagged VANGL2
or GFP alone were transduced and stably expressed in a
preneoplastic mouse mammary epithelial cell line, COMMA-D.
Respective protein expression levels were monitored (Fig. 2e) and
the cells were injected into the pre-cleared fat pad of syngeneic





































































































Figure 1 | Overexpression of VANGL2 in breast cancer. (a) Hierarchical clustering of the 208 breast cancers and 4 NB samples (columns) and the 12,304
most variable genes (rows). According to a log2 pseudocolour scale (bottom), red indicates a high level of mRNA expression compared with the median
value across all samples, whereas green indicates a low level of expression. The magnitude of deviation from the median is represented by the colour
saturation. The dendrogram of samples (above matrices) represents overall similarities in gene expression profiles. To the left of the colour matrix are
represented some biologically relevant gene clusters (orange: extracellular matrix cluster (ECM); pink: ERBB2 cluster; blue: luminal/ER cluster; green:
immune cluster; red: basal cluster). A few genes of the basal cluster are shown, including VANGL2, as well as classical basal genes (KRT5, KRT6, KRT17 and
CRYAB). (b) Box and whisker plots of VANGL2 expression across 208 breast cancer samples profiled by both expression DNA arrays and aCGH, and
according to (Student’s t-test) VANGL2 genomic status: with (left, 104 samples) versus without (right, 104 samples) gain defined as a DNA copy number
ratio tumour/NBZ1.5). (c) Box and whisker plots of VANGL2 expression across 2,687 breast cancer samples according to molecular subtypes. Expression
values are NB-centred. The horizontal black line represents the level of expression of VANGL2 in NB tissue. Differences between the subtypes were tested
for significance using one-way analysis of variance (ANOVA). For each box and whisker plot, the median value and interquartile ranges are indicated.
(d) Kaplan–Meier MFS curves in breast cancer patients according to VANGL2 mRNA expression. The 5-year MFS are 55% (upregulation; N¼ 296)
and 64% (absence of upregulation; N¼ 912). (e) Immunohistochemistry experiment using anti-VANGL2 2G4 monoclonal antibody (mAb) shows that
VANGL2 is more expressed in tumour cells (tumour) than in the stromal tissue (stroma) in basal breast cancer. Scale bar, 10mM.
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model of breast cancer, we observed that overexpressed VANGL2
caused a dramatic reduction in tumour latency, since tumour
occurrence was detectable 7 weeks post graft with VANGL2-
overexpressed cells, whereas 14 weeks were required for GFP-
expressed control cells (Fig. 2f). Overall, these data suggest that
VANGL2 overexpression participates in tumour growth in breast
cancer cell lines.
VANGL2 binds to p62/SQSTM1. To identify the molecular
mechanisms underlying the regulation of tumorigenesis by
VANGL2, endogenous VANGL2 protein complexes were
immunoprecipitated from SUM149 cells and identified using
liquid chromatography and mass spectrometry analysis. In
addition to VANGL1, a known VANGL2 partner21, a cytoplasmic
PB1 domain-containing protein, p62/SQSTM1, was identified
(Table 1 and Supplementary Data 1) in the anti-VANGL2
immunoprecipitate but not in the isotype-matched antibody
control experiment. We validated the mass spectrometry results
with western blot analysis using anti-p62/SQSTM1 antibody as a











































































































































































































































Figure 2 | VANGL2 participates in tumour growth in cell culture and murine experiments. (a) Basal cell lines chosen for their high basal
score/correlation were SUM149 r¼0.36 (a) and HCC1806 (b) r¼0.28 and threshold was 0.15. Expression of two short hairpin RNAs abrogated
VANGL2 expression in SUM149 cells by western blot analysis (upper panels). SUM149 cells (5 106) were subcutaneously inoculated into the right flank
of 4–6-week-old female NSG mice. Tumoral volume was measured at different times (lower panels). The mean and s.e.m. values (n¼6, for shLuc and
shVANGL2-transfected cells). The statistical significance between the data sets was determined using a two-way ANOVA test. *Pr0.05, **Pr0.005.
(b) Same as a using HCC1806 cells, except that 1 106 cells were inoculated into NSG mice. (c,d) Downregulation of VANGL2 with two different shRNAs
led to a decreased proliferation of SUM149 (c) and HCC1806 (d) cells. Error bars represent mean±s.d. (e) COMMA-D cells were transduced with
lentiviral supernatants allowing expression of GFP or GFP–VANGL2. Cell extracts were probed by western blot analysis with anti-GFP, -VANGL2 and
-tubulin antibodies. An asterisk pinpoints endogenous VANGL2. (f) Kaplan–Meier curve of tumour-free status of mice transplanted with COMMA-D
cells overexpressing GFP or GFP–VANGL2 (n¼ 30). The statistical significance between the data sets was determined using a log-rank test.
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(Fig. 3a) and SKBR7 (Supplementary Fig. 3) cells. Whereas
immunoprecipitated p62/SQSTM1 co-purified efficiently with
VANGL2 (Supplementary Fig. 3), the p62/SQSTM1 partner
LC3B/ATG8 (ref. 25) was not detected in the VANGL2-
associated complex (Fig. 3b), revealing the likely existence of
different pools of p62/SQSTM1. We have thus identified a
previously uncharacterized VANGL2–p62/SQSTM1 complex in
breast cancer cells.
Characterization of the VANGL2–p62/SQSTM1 interaction.
To determine whether VANGL2 is able to directly bind to its
endogenous partners, in vitro translated GFP–VANGL2 was
produced in a cell-free system and used in pulldown assays.
Glutathione S-transferase (GST)–p62/SQSTM1 (GST–p62) was
able to bind to GFP–VANGL2, whereas no binding was obvious
with the GST control protein (Fig. 3c). VANGL2 is a trans-
membrane protein presenting two cytoplasmic regions, at the
N terminus (1–102) and C terminus (242–521) (Supplementary
Fig. 3). The (242–472) sequence of VANGL2 was found to be
responsible for the p62/SQSTM1 interaction (Fig. 3c and
Supplementary Fig. 3), which is independent of the Dishevelled-
and Scribble-binding regions as shown by mutagenesis of the
VANGL2 carboxyl-terminal tail (Supplementary Fig. 3)23,26.
p62/SQSTM1 is a selective autophagy receptor and a signalling
scaffold protein harbouring PB1, Zn (zinc finger), TB (TRAF6
binding), LIR (LC3-interacting region), KIR (KEAP1-interacting
region) and UBA (ubiquitin-associated) domains (Supplementary
Fig. 3)14. To characterize the p62/SQSTM1 region required for
VANGL2 binding, a screen was carried out using a panel of
p62/SQSTM1 mutants. We found that PB1-dependent self-
association of p62/SQSTM1 (ref. 27) was dispensable for the
integrity of the complex, whereas a sequence lying carboxyl-
terminal to the LIR/KIR domains was necessary for the











































































































































Figure 3 | Identification of the signalling adapter p62/SQSTM1 as a direct binding partner of VANGL2. (a) Endogenous interaction between
VANGL2 and p62/SQSTM1 is revealed by western blot analysis after immunoprecipitation using SKBR7 cell extracts. TL is total lysate. Crtl ab is an
isotype-matched antibody. (b) The VANGL2–p62/SQSTM1 interaction occurs independently of LC3. Proteins were extracted from SUM149 cells and
co-immunoprecipitations were carried out with the indicated antibodies. LC3 co-precipitates with p62/SQSTM1 but not with VANGL2. Reciprocally,
VANGL2 co-immunoprecipitates with p62/SQSTM1 but not with LC3. IP control antibodies (IP crtl ab) are a polyclonal rabbit (for IP LC3) and a monoclonal
rat antibody (for IP VANGL2). IgHs are immunoglobulin heavy chains. (c) GST pulldown assays of in vitro translated GFP–VANGL2 (full length: WT,
N-terminal 1–102: NT, C-terminal 242–521: CT) showed that VANGL2 WT and CT directly bind to GST–p62/SQSTM1 (GST-p62) but not to GST. Asterisks
indicate in vitro translated VANGL2 (top panel) and GST (bottom panel) proteins. AR, autoradiography; CBB, Coomassie Brilliant Blue. (d) A p62/SQSTM1
peptide (p62DN) disrupts the endogenous VANGL2–p62/SQSTM1 complex. SUM149 cell protein extracts were incubated with the indicated peptides
p62DN or scrambled control peptide (Ctrl peptide) at 100mM. VANGL2 was then immunoprecipitated (IP VANGL2) and bound proteins were
immunoblotted with the indicated antibodies. TLs showed that equal amounts of proteins were present in each condition.
Table 1 | LC-MS/MS using LTQ-Velos-Orbitrap mass spectrometry analysis of proteins co-immunoprecipitated with VANGL2 in
SUM149 cell extracts.
Protein Swissprot name, accession number Sequence coverage % Mascot score No. of identified peptides Number of unique peptides
VANGL2 VANGL2_HUMAN, Q9ULK5 31 981 42 13
VANGL1 VANGL1_HUMAN, Q8TAA9 26 1078 36 10
p62 SQSTM1_HUMAN, Q13501 66 2419 65 14
Proteins identified include known protein–protein interactions, VANGL1 and novel (p62/SQSTM1) binding partners. Protein sequence coverage, Mascot score, number of peptide-spectrum matches
(identified peptides) and number of unique identified peptides are indicated for each protein. The experiment was repeated three times. Full experimental protein lists are shown in Supplementary Data 1.
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p62/SQSTM1 peptide mimicking the interaction sequence thus
identified, p62346-388 (hereafter named p62DN), and tested its
ability to inhibit the endogenous VANGL2–p62/SQSTM1
interaction in comparison with a scrambled control peptide.
A complete inhibition was observed with p62DN but not with
the control peptide used at concentration of 100 mM (Fig. 3d).
The p62DN peptide exerted dose-dependent inhibition. Indeed,
incubation of low amounts of p62DN (5 mM) was sufficient
to partially inhibit the VANGL2–p62/SQSTM1 interaction
(Supplementary Fig. 3). Further analysis with mass
spectrometry showed that p62DN treatment at 50 mM led to the
loss of interaction between p62/SQSTM1 and VANGL2, thus
confirming the western blot results (Supplementary Fig. 3 and
Supplementary Data 2). Interestingly, this experiment also
showed that the VANGL1–VANGL2 interaction, that occurs
through heterodimerization21, is unaffected by peptide inhibition,
demonstrating that VANGL2 interaction with p62/SQSTM1 is
independent of its interaction with VANGL1 (Supplementary
Fig. 3). Overall, we identify p62/SQSTM1 as a direct VANGL2
partner and describe a p62/SQSTM1 motif required for the
interaction.
Localization of the VANGL2–p62/SQSTM1 complex. To
identify the subcellular localization of the VANGL2–p62/
SQSTM1 complex in breast cancer cells, SKBR7 cells were
analysed by immunofluorescence and by confocal microscopy.
VANGL2 was found to display a predominately punctate
cytoplasmic pattern in the perinuclear region, as reported in
precedent studies28, and to colocalize with p62/SQSTM1 (Fig. 4a).
p62/SQSTM1 was previously detected in late endosomal
compartments29. To define whether VANGL2 and p62/SQSTM1
colocalize in these compartments, a three-colour immuno-
fluorescence and confocal analysis was performed with LAMP1,
a late endosomal/lysosomal compartment marker. We found a
substantial colocalization between LAMP1, VANGL2 and
p62/SQSTM1 in breast cancer cells (Fig. 4b). The colocalization
between VANGL2 and p62/SQSTM1 was further confirmed by
immunoelectron microscopy, which showed accumulation of
both markers in vesicular structures resembling endosomes/
amphisomes (Fig. 4c and Supplementary Fig. 4). Because
VANGL2 has also been described as a plasma membrane protein
in non-tumoral polarized epithelial cells21, we studied VANGL2–






























































































p62 10 nm PAG
Vangl2 15 nm PAG
Figure 4 | Colocalization of VANGL2 and p62/SQSTM1 in late endosomes. (a) Immunofluorescence staining of SKBR7 cells showed colocalization of
endogenous VANGL2 (green) and p62/SQSTM1 (red) in discrete cytoplasmic puncta. Scale bar, 10mm. The mean Pearson correlation for VANGL2 and
p62/SQSTM1 is 0.62, calculated using the Image J software for B15 cells per field of view and from 10 images. (b) Partial colocalization of VANGL2 and
p62/SQSTM1 in late endosomes of SKBR7 cells stained with the LAMP1 marker. Scale bar, 20mm. (c) SKBR7 ells were cultured in a nutrient-deprived
medium and treated with 100 nM bafilomycin A1 (6 h) before fixation. Double labelling against VANGL2 (arrowheads) and p62/SQSTM1 (arrows),
as described in Methods, showed accumulations of both markers in vesicular structures probably resembling endosomes/amphisomes. Scale bar, 200 nm.
(d) IMCD3 cells were treated with PBS or EGTA (5 mM) for 30 min. Immunofluorescence and confocal analysis were performed using the indicated
antibodies. Scale bar, 10mm. Inserts show colocalized VANGL2 and p62/SQSTM1. (e) The VANGL2–p62/SQSTM1 complex was recovered in confluent
SKBR7 or IMCD3 cells with 2G4 mAb (IP VANGL2) but not a control antibody (IP IgG2a ctrl) as seen using western blot analysis with the indicated
antibodies. The complex was more abundant in cancer cells (SKBR7) than in polarized cells (IMCD3). Note that human (SKBR7 cells) and murine (IMCD3
cells) p62/SQSTM1 run at different molecular weights. (f) Lysates of confluent IMCD3 cells treated for 30 min with PBS or EGTA were subjected to 2G4
mAb immunoprecipitation (IP VANGL2). Immunoprecipitated proteins were probed by western blot analysis with the indicated antibodies. Increased
amounts of VANGL2–p62/SQSTM1 complexes were recovered after EGTA treatment.
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cells. In these cells, as expected, VANGL2 is strongly recruited
to the plasma membrane and nicely colocalizes with b-catenin at
cell–cell contacts (Supplementary Fig. 4). It shows weak
colocalization with p62/SQSTM1 in intracellular vesicles (Fig. 4d,
upper panels). In contrast, SKBR7 cells poorly polarize,
as shown by the irregular b-catenin staining, and have barely
detectable plasma membrane VANGL2 (Supplementary Fig. 4).
Co-immunoprecipitation between VANGL2 and p62/SQSTM1
was more efficient in SKBR7 than in IMCD3 cells despite a
stronger expression of VANGL2 in IMCD3 cells and comparable
amounts of p62/SQSTM1 in both cell types (Fig. 4e). When the cell
junctions of polarized IMCD3 cells were disrupted by adding a
calcium chelation agent (EGTA), VANGL2 relocalized from the
plasma membrane to intracellular vesicles, and its colocalization
(Fig. 4d, lower panels) and co-immunoprecipitation with
p62/SQSTM1 (Fig. 4f) increased. Altogether, these data suggest
that the VANGL2–p62/SQSTM1 colocalization occurs in part in
late endosomal compartments in breast cancer cells and is
regulated by cell junction formation.
Because p62/SQSTM1 plays a key role in the autophagic
degradation of polyubiquitinylated proteins14, it was important to
establish whether VANGL2 is degraded by autophagy. Inhibition
of autophagy by serum starvation and mammalian target of
rapamycin (mTOR) inhibition (rapamycin treatment) led to the
expected cleavage of LC3, whereas VANGL2 levels remained
unchanged in western blot experiments (Supplementary Fig. 4).
Moreover, no change in the VANGL2 expression level was
observed in mouse embryonic fibroblasts lacking p62/SQSTM1
GFP-p62DN
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Figure 5 | The VANGL2–p62/SQSTM1 complex regulates JNK phosphorylation. (a) Downregulation of VANGL2 in SUM149 cells using a specific shRNA
led to reduced JNK phosphorylation induced by Wnt5a (100 ng ml 1 for the indicated times). JNK is represented by two isoforms: p54 and p46. Wnt5a
led to p46 (phospho-p46) and not p54 (phospho-54) phosphorylation. Relative quantification of immunoblots (phosphorylated JNK/total JNK) is
representative from three independent experiments and use of two different shRNAs. (b) Expression of GFP-p62DN, but not GFP, in SUM149 cells led to
decreased p46 JNK phosphorylation (phospho-46) induced by 100 ng ml 1 of Wnt5a at the indicated times. Relative quantification of immunoblots
(phosphorylated JNK/total JNK) is representative from three independent experiments. (c) SUM149 cell extracts were added with the control peptide
(Ctrl peptide) or the p62/SQSTM1 peptide (p62DN) that inhibited recruitment of JNK and p62/SQSTM1 to VANGL2. (d) Proteins extracted from SUM149
cells treated or not with serum were immunoprecipitated with anti-VANGL2 antibody and blotted with the indicated antibodies. p62/SQSTM1, JNK and
phosphorylated JNK (phospho-p54 and phospho-p46) were present in the VANGL2 complex.
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Figure 6 | p62/SQSTM1 is necessary for VANGL2 pathway-mediated in vivo morphogenesis. (a) Two-cell embryos were injected in each blastomere
with 12.5 (n¼ 15), 25 (n¼ 13) and 50 (n¼ 104) ng of p62 MO. Morphology was analysed at tailbud stage. (b) Embryos injected with 50 ng of p62 MO
were processed for WISH analysis at mid-neurula and late gastrula stages. Convergence extension in the neural tube of late neurula embryos was evaluated
by the average length/width ratio of the Sox2 domain (n¼ 17). Convergence extension in the axial mesoderm of late gastrula embryos was evaluated by the
average length of the Xbra domain (n¼ 16). Tailbud embryos were stained with the Sox2 probe to highlight neural tube defect (bottom panel, n¼ 30 control,
n¼ 104 morphants). (c) Two-cell embryos were injected in each blastomere with 11.5 ng of VANGL2 MO (n¼ 27), 8 ng of p62 MO (n¼ 26) or 11.5 ng of
VANGL2þ8 ng of p62 MO (n¼ 32). Morphology was analysed at the tailbud stage using criteria of a. These embryos were processed for analysis of Sox2
expression at the tailbud stage (n¼ 3). (d) Ten embryos injected as in b or with 34.5 ng of VANGL2 MO in each blastomere were collected at stage 13 and
processed for RT–qPCR. (e) Four-cell embryos injected with Wnt5a mRNA (30 pg per cell) in the animal pole received a second injection of VANGL2
(11.5 ng per cell), or p62 (12.5 ng per cell) in all animal blastomeres at eight-cell stage. Fifteen animal caps per condition were isolated at the blastula stage,
cultured for 4 h (at 23 C) and then processed for RT–qPCR. (f) Two-cell embryos were injected in each blastomere with 4.5 ng of control peptide (n¼ 27)
or p62DN peptide (n¼ 26). Morphology was analysed as in a and processed for analysis of Sox2 expression at the tailbud stage. (g) Ten embryos injected
as in f were collected at stage 13 and processed for RT–qPCR. For qPCR graphs, error bars represent s.e.m. values of three or more independent
experiments with two technical duplicates. Statistical analyses used unpaired Student’s t-test, except in e where one-way ANOVA with Dunnett’s test
(99.9% confidence intervals) were applied. *Pr0.05; **Pr0.005; ***Pr0.0005; Ctrl, control; MO, morpholino; mRNA, messenger RNA; RT–qPCR,
reverse transcriptase–quantitative PCR; WISH, whole-mount in situ hybridization.
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Figure 7 | Disruption of the VANGL2–p62/SQSTM1 interaction in breast cancer cells. (a) Kaplan–Meier MFS curves of breast cancer patients according
to concomitant VANGL2 and p62/SQSTM1 mRNA expression. The 5-year MFS are 49% (both upregulated; N¼ 27), 64% (both not upregulated; N¼ 833)
and 56% (one upregulated, the other not upregulated; N¼ 79 and N¼ 269). (b) Soft agar colony formation of T47D cells overexpressing GFP,
GFP–VANGL2 and GFP–p62/SQSTM1 (right). Protein expression was revealed with anti-p62/SQSTM1, anti-VANGL2 and anti-GFP antibodies by western
blot analysis (right). In anti-GFP blot, the arrowhead indicates position of co-migrating GFP–VANGL2 and GFP–p62/SQSTM1 and the asterisk pinpoints GFP
alone. Error bars represent mean±s.d. (n¼ 3). (c) Protein levels of VANGL2, phosphorylated JNK, JNK (p54/p46), p62/SQSTM1 and tubulin assessed in
eight breast cancer PDXs (PDX 1–8) by western blot analysis. (d) VANGL2, JNK, phosphorylated JNK and tubulin signals from 30 PDX protein extracts
were quantified. VANGL2/tubulin ratios were plotted against pJNK/JNK ratios, arranged in ascending order into three equally sized groups (low, medium
and high). High expression of VANGL2 protein is correlated to high levels of phosphorylated JNK. Box and whisker plots show the median value and
interquartile ranges. The Kruskal–Wallis test was used for comparison of the median levels of expression. Statistically significant differences are indicated
(*Pr0.05; **Pr0.01). (e) Treatment of the indicated PDX-derived cells (PDX. DC-2,  27,  13 and  26) with a Tat-conjugated JNK inhibitor (Tat-JIP at
10mM) during 48 h led to greater reduction in cell proliferation of VANGL2high/pJNKhigh than VANGL2low/pJNKlow PDX-derived cells. Comparisons use
Tukey’s multiple comparisons test. NS, not significant. Data are representative of three independent experiments; *Pr0.05; **Pr0.01; ***Pr0.001;
****Pr0.0001. (f) Treatment of the indicated PDX-derived cells (PDX. DC-2,  27,  13 and  26) with the p62DN peptide (225mM) but not with control
scrambled peptide (225 mM) during 48 h resulted in decreased cell proliferation of VANGL2high/pJNKhigh, but not VANGL2low/pJNKlow, PDX-derived cells.
Data are representative of three independent experiments and statistical testing as stated in e.
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expression on autophagy induction or inhibition (Supplementary
Fig. 4). These results showed that VANGL2 is resistant to
autophagic degradation. In contrast, we found that VANGL2 was
sensitive to a proteasome degradation pathway (Supplementary
Fig. 4), as was previously described for its paralogue VANGL1
(ref. 30).
p62 recruits JNK to VANGL2 and contributes to its activation.
To determine the role of p62/SQSTM1 in VANGL2 signalling,
we assessed its impact on the regulation of JNK activation,
a well-known downstream effector of VANGL2 (ref. 26),
represented by two isoforms p54 and p46. For this purpose, we
first confirmed that stimulation of SUM149 cells with WNT5A, a
Wnt/PCP ligand, leads to JNK activation as monitored by the
phosphorylation state of p46 JNK, in a VANGL2-dependent
manner. As illustrated in Fig. 5a, on WNT5A stimulation,
depletion of VANGL2 by a specific short hairpin RNA (shRNA)
led to a significant reduction in p46 JNK phosphorylation
compared with shLuc control cells. As observed for VANGL2,
p62/SQSTM1 depletion by two different short interfering RNAs
(siRNAs) led to a two- to threefold decrease in JNK phosphor-
ylation in response to WNT5A treatment, suggesting that JNK
activation by this WNT ligand is dependent on VANGL2 and
p62/SQSTM1 (Supplementary Fig. 5).
We assessed whether the VANGL2–p62/SQSTM1 interaction
contributes to JNK phosphorylation using GFP-p62DN, a fusion
protein containing the inhibitory p62DN peptide (Fig. 3e), which
is able to inhibit the VANGL2–p62/SQSTM1 interaction as
revealed by co-immunoprecipitation experiments (Supplementary
Fig. 5). Overexpression of GFP-p62DN impaired JNK phosphor-
ylation following WNT5A stimulation (Fig. 5b), suggesting that
JNK activation by WNT5A requires integrity of the VANGL2–
p62/SQSTM1 complex. This result led us to investigate a possible
molecular link between JNK and the VANGL2–p62/SQSTM1
complex. We thus carried out immunoprecipitations of VANGL2
in the presence of p62DN or control soluble synthetic peptides
and looked for JNK interaction. As illustrated in Fig. 5c, JNK was
detectable in VANGL2 immunoprecipitates only when the
VANGL2–p62/SQSTM1 interaction was preserved. This result
was confirmed by immunoprecipitation of proteins extracted
from SUM149 cells treated by a p62/SQSTM1 siRNA. Under such
conditions, JNK was unable to interact with VANGL2
(Supplementary Fig. 5). Finally, we addressed whether the
interaction between JNK and the VANGL2–p62/SQSTM1
complex was modulated by activation in co-immunoprecipitation
experiments (Fig. 5d and Supplementary Fig. 5). We observed
that serum or Wnt5a stimulation did not affect VANGL2–
p62/SQSTM1 complex formation or its interaction with JNK.
JNK was found to be phosphorylated on stimulation and
remained associated with the VANGL2–p62/SQSTM1 complex.
Altogether, we provide compelling evidence that, in breast cancer
cells, WNT5A–VANGL2 signalling requires the integrity of
the VANGL2–p62/SQSTM1 complex to associate with and
phosphorylate JNK.
p62/SQSTM1 is involved in a conserved WNT5A–VANGL2–
JNK signalling pathway. To determine whether the VANGL2–
p62/SQSTM1 complex and its involvement in JNK signalling is
uniquely linked to pathological conditions, or whether it also has
a physiological relevance, we tested its involvement in Xenopus
embryogenesis26,31. First, we confirmed that p62/SQSTM1 is
conserved in Xenopus (Supplementary Fig. 6). We found that the
expression pattern of p62/SQSTM1 overlaps with that of VANGL2
(ref. 31) as both genes are rather ubiquitously expressed during
gastrulation and neurulation (Supplementary Fig. 6). Inhibition
of the function of p62/SQSTM1 by injection of a morpholino
oligonucleotide (MO) led to VANGL2-like dose-dependent
phenotypes31 including incomplete neural tube closure and
severely reduced axial elongation (Fig. 6a,b). As typically
observed when Wnt/PCP activity is perturbed, mesoderm and
neural tissue cells were normally specified in p62/SQSTM1
morphant embryos, but their capacity to undergo convergence
extension was severely impaired (Fig. 6b). Embryos developed
normally when injected with a p62/SQSTM1 MO carrying five
mismatches (Supplementary Fig. 6). In contrast, a second
independent MO targeting p62/SQSTM1 50 untranslated repeat
also caused neural tube defects, albeit at lower frequency
(Supplementary Fig. 6). To check whether the most active
p62/SQSTM1 MO induced a specific phenotype, we performed a
rescue assay with a construct encoding the human p62/SQSTM1
protein (Supplementary Fig. 6). We observed that expression of
human p62/SQSTM1 could efficiently reduce morphological
anomalies caused by Xenopus p62/SQSTM1 knockdown in
tailbud embryos, and correct blastopore closure, convergent
extension and neural tube closure. The observed rescue further
confirmed the functional conservation of p62/SQSTM1 proteins
between Xenopus and human. The anticipated cooperation
between VANGL2 and p62/SQSTM1 was demonstrated by
concomitant knockdown, using suboptimal amounts of the
respective MOs, which yielded stronger phenotypes than
separate injections (Fig. 6c).
We next tested whether VANGL2 and its partner p62/SQSTM1
are required for JNK-mediated gene expression in Xenopus.
Expression of a Wnt/PCP effector gene Xenopus Paraxial
Protocadherin (xPAPC)32, which is controlled by a WNT5A/
JNK pathway33, was downregulated by knockdown of VANGL2
and p62/SQSTM1 in developing embryos, or following Wnt5A
mRNA injection in animal caps (Fig. 6d,e). The physiological
importance of the VANGL2–p62/SQSTM1 interaction was
assessed by injection of the competing human p62DN peptide
(Fig. 3e), which has extensive similarities with the corresponding
Xenopus sequence. Treatment with this peptide, but not with the
scrambled peptide, caused severe neural tube closure defects and
reduced xPAPC expression, suggesting that JNK signalling
was impaired (Fig. 6f,g). From these experiments, we conclude
that p62/SQSTM1 expression, as well as interaction with
VANGL2, contribute to VANGL2-dependent functions in
Xenopus. We have thus assigned p62/SQSTM1 to a conserved
WNT5A–VANGL2–JNK signalling pathway required for proper
morphogenesis of the Xenopus embryo.
VANGL2–p62/SQSTM1–JNK signalling in breast cancer.
p62/SQSTM1 has been associated with poor prognosis in various
types of cancer, and functions as an oncogenic adaptor
protein18,19. We next addressed whether the VANGL2–p62/
SQSTM1 complex and its associated JNK signalling pathway have
a significance in tumour progression. Our patient breast cancer
data show that upregulation of p62/SQSTM1 tended to be
associated with poor MFS (5-year MFS 54% versus 62%, log-rank
test, P¼ 0.088; not shown) in agreement with published
work18,19. A multivariate analysis of VANGL2 and p62/SQSTM1
expression based on the Akaike information criterion highlighted
cooperation between these two genes in prognostic term (Fig. 7a).
The functional cooperation between VANGL2 and p62/SQSTM1
was confirmed in vitro in anchorage-independent assays by the
apparent increase in tumorigenicity of breast cancer cells
ectopically co-expressing VANGL2 and p62/SQSTM1 (Fig. 7b).
In addition, expression of the dominant-negative GFP-p62DN in
SUM149 cells led to a significant decrease in cell migration
(Supplementary Fig. 7), suggesting that this effect is due to
the destabilization of the VANGL2–p62/SQSTM1 complex.
To evaluate whether the p62DN sequence alone is able to
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elicit a similar effect, the peptide was fused to a fluorescent
cell-penetrating fluorescein isothiocyanate (FITC)-Tat peptide
(FITC-Tat-p62DN). This chimeric peptide was as efficient as the
p62DN peptide devoid of FITC-Tat to inhibit the VANGL2–p62/
SQSTM1 interaction (Fig. 3e) in co-immunoprecipitation assays
using similar concentration ranges (Supplementary Fig. 7). When
membrane-permeant peptides were added to the culture media of
breast cancer cells, a specific decrease in cell proliferation was
detected in high VANGL2-expressing cells (SUM149 and
HCC1806) with FITC-Tat-p62DN peptide, but not with the
control peptide (Supplementary Fig. 7). Interestingly, when the
same experiment was carried out on the low VANGL2-expressing
T47D cell line, neither FITC-Tat-p62DN nor the control peptide
had any significant effect on the proliferation rate. These results
suggest that the effect of FITC-Tat-p62DN depends on the
expression of VANGL2 and of its interaction with p62/SQSTM1,
and has no intrinsic antiproliferative properties. To challenge this
point in experiments akin to pathological situations, we used
recently characterized breast cancer PDXs that retain the
histopathological and molecular features of the original primary
tumours34. Thirty breast cancer PDXs were characterized for
VANGL2 and p62/SQSTM1 expression as well as JNK activation
levels with western blot analysis (Fig. 7c). While variations of the
levels of p62/SQSTM1 and JNK appeared modest, those of
VANGL2 as well as phospho-JNK were more striking. We
quantified the expression levels of VANGL2, tubulin, JNK and
phospho-JNK in our PDX series and plotted the VANGL2/
tubulin against the phospho-JNK/total JNK ratios (Fig. 7d). A
correlation was found between VANGL2 and phospho-JNK
signal intensities (R2¼ 0.494, where R2 is the coefficient
of determination), and differences between low, medium and
high expression of phospho-JNK with VANGL2 expression
were observed. A similar analysis revealed no correlation
between
p62/SQSTM1 and phospho-JNK signal intensities (R2¼ 0.043).
The presence of the VANGL2–p62/SQSTM1 complex in breast
cancer PDX protein extracts was confirmed by VANGL2
immunoprecipitation followed by western blot analysis
(Supplementary Fig. 7). We then addressed whether the
VANGL2–p62/SQSTM1 complex and associated JNK activation
contribute to cell proliferation. To this aim, the sensitivity to
membrane-permeant peptides inhibiting either JNK activation
(Tat-JIP) or destabilizing the VANGL2–p62/SQSTM1 interaction
(FITC-Tat-p62DN) was evaluated in a proliferation assay on four
breast cancer PDX-derived cell lines expressing high (PDX 13 and
26) or low (PDX 2 and 27) levels of VANGL2 that correlated with
phospho-JNK contents (Supplementary Fig. 7). PDX-derived cells
with a VANGL2high/pJNKhigh phenotype were found to be more
proliferative and more sensitive to JNK inhibition than
VANGL2low/pJNKlow PDX-derived cells (not shown). Indeed,
as illustrated in Fig. 7e, treatment with the Tat-JIP peptide led to a
stronger reduction in cell proliferation in VANGL2high/pJNKhigh
cells (60–70% reduction) than in VANGL2low/pJNKlow cells
(20–30% reduction). Moreover, only VANGL2high/pJNKhigh
PDX-derived cells showed a significant decrease in cell prolifera-
tion and JNK phosphorylation on incubation with the FITC-
Tat-p62DN, whereas the control peptide had no effect (Fig. 7f and
Supplementary Fig. 7). Taken together, these data show that
overexpression of VANGL2 in breast cancer cells correlates with
JNK activation and cell proliferation, which is sensitive to
inhibition of the VANGL2–p62/SQSTM1 interaction.
Discussion
The canonical b-catenin-dependent Wnt signalling is a molecu-
larly well-defined pathway known to be involved in breast cancer
progression for many years3. In contrast, the role of the non-
canonical Wnt/PCP pathway in this disease and the underlying
molecular mechanisms are much less well understood.
Here we find that the non-canonical Wnt/PCP VANGL2 gene
is linked to a basal signature and is overexpressed in breast
cancers with poor prognosis (Fig. 1). In our data set, 23% of
breast cancers showed VANGL2 mRNA upregulation with a good
correlation with gene amplification. In agreement with our
findings, a recent study concluded that VANGL2 is frequently
overexpressed in endocrine-related cancers, among which 24%
are invasive breast carcinoma35. In contrast, upregulation of the
paralogue gene VANGL1 is observed in less than 5% of invasive
breast carcinoma and is associated with increased relapse rate and
reduced survival in luminal breast cancers, suggesting a
differential contribution of the VANGL family members to
breast tumorigenesis8,35.
Until now, functional studies gathered in breast cancer cells on
the VANGL family have focused on VANGL1 and have led to the
conclusion that this Wnt/PCP protein plays a role in cell motility
and invasiveness, with no obvious involvement in tumour
growth7,8. The closely related VANGL2 protein is also endowed
with promigratory functions in chronic lymphoid leukaemia,
epithelial cells and fibroblasts23,36. Using cell culture and murine
assays, we now demonstrate that VANGL2 is involved in breast
cancer cell migration, anchorage-dependent and -independent
cell proliferation as well as tumour growth (Fig. 2). Results
obtained in cultured cell lines were confirmed in breast cancer
PDX-derived cells that grow at higher cell proliferation rate in the
context of VANGL2 overexpression (Fig. 7). These results suggest
that VANGL2, a core Wnt/PCP component, participates in the
growth of breast cancer cells.
To gain insight into the molecular mechanism underlying the
role of VANGL2 in this disease, we purified the VANGL2 protein
complex and identified p62/SQSTM1, a PB1 domain-containing
protein with oncogenic functions as a VANGL2-binding partner
(Fig. 3). We demonstrate the involvement of this scaffold protein
in VANGL2–JNK signalling. Indeed, p62/SQSTM1 directly
interacts with the carboxyl-terminal region of VANGL2 and
recruits JNK, a downstream component of the Wnt/PCP
pathway3, thus promoting its phosphorylation (Fig. 5). The
results obtained in breast cancer cells and in Xenopus show the
existence of an evolutionarily conserved WNT5A–VANGL2–
p62/SQSTM1–JNK signalling pathway (Fig. 6).
In breast cancer PDXs, a good correlation was found between
levels of VANGL2 and phosphorylated JNK (Fig. 7). Recent data
have linked cell polarity, JNK and cell proliferation in breast
tumours. Indeed, loss of PAR3, a major regulator of apicobasal
polarity, leads to JNK-mediated proliferation of transformed
mammary cells and tumour development in a RAC1-dependent
manner37. Because VANGL2 binds to RAC1 (ref. 38), it is
possible that this small GTPase contributes to the VANGL2–p62/
SQSTM1–JNK pathway in breast cancer cells. The involvement of
the scaffold JNK-interacting protein (JIP1) in JNK activation is
also likely, as VANGL2high/pJNKhigh PDX-derived cells were
sensitive to TAT-JIP, a peptidic inhibitor derived from JIP1
(Fig. 7). JIP1 coordinates JNK signalling by recruiting MAPK
Kinases (MKKs), such as MKK4/MKK7, and JNK39. As JNK
constitutively binds to the VANGL2–p62/SQSTM1 complex and
becomes phosphorylated solely on stimulation, we propose that
JIP1/MKKs are involved in this activation step. Other studies
have assigned a role of Wnt/PCP deregulation in the activation
of the Hippo and FYN-STAT3 pathways, which, respectively,
promote breast cancer stem cell renewal and EMT9,40. Thus,
key steps of breast cancer development (initiation, growth and
spread) are likely controlled by different Wnt/PCP-related
signalling events.
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In polarized epithelial tissues, VANGL2 is present in endocytic
compartments28 and at the plasma membrane where it interacts
in trans with Frizzled receptors41,42. We confirmed the plasma
membrane localization of VANGL2 in polarized IMCD3 cells
(Fig. 4). In SKBR7 breast cancer cells, we found a poor
recruitment of VANGL2 at the plasma membrane, likely due to
the loss of cell junctions. In agreement with this hypothesis, loss
of epithelial cell–cell contacts following EGTA treatment
redirected VANGL2 to endosomal compartments and increased
its interaction with p62/SQSTM1 (Fig. 4). In addition, consistent
with this idea, the interaction between VANGL2 and p62/
SQSTM1 is required for convergence extension of nonepithelial
tissues in Xenopus embryos (Fig. 6). Loss of cell polarity
commonly observed in carcinomas and during EMT could thus
favour the formation of VANGL2–p62/SQSTM1 complex and the
subsequent JNK-mediated cell proliferation. Interestingly, it was
recently reported that p62/SQSTM1 regulates levels of junctional
proteins and that its overexpression induces EMT. Upregulation
of p62/SQSTM1 may thus have multiple outcomes, each of which
contributes to breast cancer aggressiveness19,20.
The colocalization of VANGL2–p62/SQSTM1 in late
endosomes and its role in JNK activation is reminiscent of
previous work reporting JNK signalling in endosomes.
Indeed, phosphorylated JNK has been recently localized in
LAMP1-positive late endosomes together with its signalling
partners, the B-cell receptor and Ezrin43. Interestingly,
p62/SQSTM1 was shown to recruit mTOR to the lysosomal
membrane, which stands as an important hub for this pathway44.
We thus suggest that VANGL2–p62/SQSTM1-JNK signalling
occurs in part in late endosomal compartments.
The basal breast cancer subtype is associated with higher
mortality than the other subtypes because of the poor success of
current therapies. Our finding that VANGL2–p62/SQSTM1–JNK
signalling is upregulated in this disease leads us to consider its
components as potential therapeutic targets. This is actually the
case for JNK that has become a target for drug development in
metabolic diseases, inflammation and cancer. However, because it
plays a pivotal role in numerous biological functions, inhibition of
JNK is predicted to have significant side effects45. p62/SQSTM1
could represent an alternative therapeutic target, as its
degradation can be triggered by induction of autophagy using
rapamycin-like drugs such as everolimus. According to our
results, this strategy should mimic the results obtained with
p62/SQSTM1 siRNA and impair JNK signalling in breast cancer
cells (Supplementary Fig. 5). Promising results have been recently
obtained with everolimus in preclinical assays46 and clinical trials
in basal breast cancers47. On the other hand, autophagy
inhibition may also enhance therapeutic response to
chemotherapy48. The potential of targeting autophagy in basal
breast cancer deserves further investigation. Over the course of
our study, we have identified a peptide able to destabilize the
VANGL2–p62/SQSTM1 complex, and to impair JNK signalling
and cell proliferation of breast cancer cells. This blocking strategy
may represent a more specific, and possibly, less harmful
alternative to inhibit VANGL2–p62/SQSTM1–JNK signalling in
VANGL2-overexpressing breast cancers.
Methods
Cell culture and cell transfection and knockdown experiments. All epithelial
breast cancer cell lines (T47D, HCC1806 and SUM149) were purchased and grown
in accordance with American Type Culture Collection recommendations. SKBR7
(National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO): GSM75171 record,epithelial breast tumour cell line
SKBR7_b39_s31 (Homo sapiens)) cells were grown in RPMI or F12 medium
supplemented with 100 U ml 1 of penicillin, 100 mg ml 1 of streptomycin and
10% heat-inactivated fetal bovine serum. All cell lines were tested negative for
mycoplasma contamination. Murine epithelial IMCD3 cell line was cultured in
DMEM/F12 growth media. T47D cells were transfected with pEGFP using
Lipofectamine 2000 reagent according to the manufacturer’s instructions
(Invitrogen). SUM149 cell nucleofection was performed according to the
manufacturer’s protocol (Amaxa). Nutrient deprivation was achieved by incubating
cells with Earle’s balanced salt solution (EBSS) or Hank’s balanced salt solution
(HBSS) (GIBCO). Bafilomycin A1 and puromycin (Sigma) were used at the
specified concentrations and for the indicated time. Rapamycin (Calbiochem) was
used at the specified concentration and for the indicated time.
Animal models. All mouse husbandry and experimental procedures were
performed in accordance with the protocols approved and in compliance with
policies approved by the local Committee for Animal Experimentation (CAE of
Provence number 14) of Marseille, France (2–091009). NSG mice were obtained
from Charles Rivers (UK). Mice were housed under sterile conditions with
sterilized food and water provided ad libitum and were maintained on a 12-h
light and 12-h dark cycle. SUM149 (5 106) and HCC1806 cells (1 106) were
subcutaneously inoculated into the right flank of 4–6-week-old female NSG mice.
Tumour growth was monitored by measuring with a digital caliper and by
calculating tumour volume (lengthwidth2p/6). No blinding was used. For
in vivo VANGL2-overexpression tumorigenesis experiments, COMMA-D cells
were injected into cleared fat pads of 4-week-old female BALB/c as previously
described24. Mice were examined weekly for palpable tumours. Once palpable
tumours were found, they were measured with calipers weekly. Mice were killed
when the calculated tumour volume reached 1 cm.
Xenopus experiments. Xenopus embryo collection, microinjection, whole-mount
in situ hybridization, animal cap assays and xPAPC reverse transcriptase–
quantitative PCR conditions have all been described previously49. The riboprobe
against Xenopus p62/SQSTM1 was derived from the commercial plasmid IMAGE
clone 8541876 (Biovalley, France). The MOs used in this study were purchased
from GeneTools. Their respective sequences are as follows: p62/SQSTM1: 50-AGG
CTTTCACGGTGACCGTCATGTT-30 ; p62/SQSTM1 5mis-MO: 50-AGCCTTTCA
CCGTCACCCTCATCTT-30 ; p62/SQSTM1 MO2: 50-CAATGCACCTGACAGGC
GGTGAT-30.
VANGL2 mRNA expression analysis in breast cancer samples. Samples of
human origin and associated data were obtained from the IPC/CRCM Tumour
Bank that operates under authorization # AC-2007-33 granted by the French
Ministry of Research (Ministère de la Recherche et de l’Enseignement Supérieur).
Before scientific use of samples and data, patients were appropriately informed and
asked to consent in writing, in compliance with French and European regulations.
The project was approved by the IPC Institutional Review Board (Comité
d’Orientation Stratégique).
To determine VANGL2 mRNA expression in breast cancer and NB, we
analysed gene expression data generated by our laboratory coupled with publicly
available data sets. Our series included tumour tissues from 330 patients with
invasive adenocarcinoma and four pools of NB tissue samples (11 healthy women).
The 14 public data sets comprising one probe set representing VANGL2 were
collected from the NCBI/Genbank GEO database, the European Bioinformatics
Institute ArrayExpress database or at the authors’ websites (Supplementary
Table 3). This resulted in a total of 2,687 nonredundant invasive breast cancers
with VANGL2 mRNA expression and histoclinical data available for analysis. For
the Agilent-based data sets, we applied quantile normalization to available
processed data. Regarding the Affymetrix-based data sets, we used Robust
Multichip Average50 with the nonparametric quartile algorithm as normalization
parameter. Before analysis, expression level for each tumour was centred by the
average expression level of the four NB samples. To be comparable across data sets
and to exclude bias from population heterogeneity, VANGL2 expression levels were
standardized within each data set using the luminal A population as reference. All
steps were performed in R using Bioconductor and associated packages. VANGL2
upregulation in a tumour was defined by a ratio tumour/NB Z2, downregulation
by a ratio r0.5 and no deregulation by a ratio 40.5 and o2. The molecular
subtypes of tumours were defined using the PAM50 Predictor51. To investigate the
mRNA expression of VANGL2 in mammary cell lines, we explored our previously
published gene expression data of 35 cell lines, including SKBR7 and SUM149,
profiled using oligonucleotide microarrays22.
VANGL2 DNA copy number analysis in breast cancer. We analysed aCGH data
of 208 breast cancers profiled in our laboratory using 244-K CGH microarrays
(Hu-244A, Agilent Technologies) as previously described52. A pool of 13 normal
male DNA had been used as reference. Extraction of data (log2 ratio) was carried
out with CGH Analytics, whereas normalized and filtered log2 ratio was obtained
from the ‘Feature Extraction’ software (Agilent Technologies). The VANGL2 locus
at 1q21-q23 was analysed and copy number changes were characterized as reported
previously53. Four probes (A_16_P35329154, A_16_P00175662, A_16_P35329208
and A_16_P35329224) matched the VANGL2 gene on our Agilent chips. A DNA
copy number alteration in a tumour was defined as 1.5-fold change as compared
with normal DNA.
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Clinical statistical analysis. To compare the distribution according to categorical
variables, we used the Fisher’s exact test. The prognostic value of VANGL2
deregulation was analysed in the subgroup of 1,208 nonstage IV patients with
available follow-up. MFS was calculated from the date of diagnosis until the date of
first metastatic relapse. Follow-up was measured from the date of diagnosis to the
date of last news for patients without relapse. A total of 492 patients experienced
metastatic relapse after a median time of 25 months from diagnosis, and 716
remained relapse-free with a median follow-up of 84 months. Survival was
calculated using the Kaplan–Meier method and curves were compared with the
log-rank test. The 5-year MFS was 62% (95% confidence interval, 59–65%) for the
whole population. Univariate and multivariate survival analyses were performed
using Cox regression analysis (Wald test). Variables tested in univariate analyses
included patients’ age at the time of diagnosis (r50 versus 450 years) and
pathological features including type, tumour size (pT: pT1 versus pT2–3), axillary
lymph node status (pN: negative versus positive), grade (1 versus 2–3), IHC ER,
PR and ERBB2 status (negative versus positive) and VANGL2 deregulation
(upregulation versus no upregulation). Variables with a P valueo0.05 in univariate
analysis were tested in multivariate analysis. To compare the prognostic value
of VANGL2 and p62/SQSTM1/SQSTM expression alone and in combination,
we used multivariate analysis based on the choice of the best predictive model by
minimization of the Akaike criterion (AIC) in a stepwise algorithm using both
forward and backward directions. All statistical tests were two-sided at the 5% level
of significance. Statistical analysis was performed in R and associated packages.
We followed the reporting REcommendations for tumour MARKer prognostic
studies (REMARK criteria)54.
Experimental statistical analysis. Each data panel is representative of at least
three independent replicate experiments. The s.d. or the s.e.m. are displayed and
stated in each experiment. Further analysis of variance and subsequent ad hoc
comparisons used Mann–Whitney, Student’s t-tests or analysis of variance
followed by Tukey’s test (95% confidence intervals) using the GraphPad Prism
software.
Knockdown experiments. ShVANGL2 (targeting the 50 untranslated repeat
region 50-GAGCGCTGCGGATACAAAG-30 sequence and 50-GTACCTTCGGAC
CACCAAG-30) cloned into the pSUPER.retro.puro vector (OligoEngine) was
transfected and selected in 0.5 mg ml 1 puromycin for stable reduction of
VANGL2 protein expression in SUM149 cells. A shRNA control targeting the
Luciferase protein (shLuc) was used in these experiments55. The VANGL2 siRNA
(05: 50-GCACCAAGAAGGUCCCAUU-30 , 06: 50-GGGAUGAGCGGGAUGA
CAA-30 , 07: 50-GACCGACACCGCUCUAAGA-30, 08: 50-GAUCCCAAGUCACA
CAAGU-30), the p62/SQSTM1 siRNA (05: 50-GAACAGATGGAGTCGGATA-30,
06: 50-GCATTGAAGTTGATATCGAT-30 , 07: 50-CCACAGGGCTGAAGGA
AGC-30 , 08: 50-GGACCCATCTGTCTTCAAA-30) and non-targeting siRNA
controls are from Dharmacon. siRNA transfections were carried out with
RNAiMAX (Invitrogen), as recommended by the supplier. Lentiviral vectors
(PSL9-Venus-P62/SQSTM1-FGT and PSL9-ctrl) were used to produce highly
concentrated virion particles (Vectorologie, Montpellier, France).
Peptide production and peptide inhibitors. FITC-Tat-p62DN (VDPSTGELQ
SLQMPESEGPSSLDPSQEGPTGLKEAALYPHLPP) and FITC-Tat-Scrambled
(EQQPEGSLVPGSPSEDTHLLDQPPGLLSPAEPEMTSPLKASYG) peptides were
synthesized by GenScript, USA. A FITC-Tat (YGRKKRRQRRR) cell-penetrating
sequence was fused at the N-terminal end of peptides. JNK inhibitor II is from
Calbiochem (Catalogue No. 420119).
Antibodies. Monoclonal rat anti-VANGL2 (2G4 monoclonal antibody) was
generated as described21. Anti-p62/SQSTM1 antibodies used in the study are as
follows: mouse antibody (BD Biosciences 610833) or M01, clone 2C11, for EM
experiments (Abnova: H00008878-M01) and guinea-pig polyclonal anti-p62
(Progen Biotechnik, GP62-C). Other antibodies used are as follows: rabbit antibody
to LC3 (MBL Technology: PM036), rabbit antibody to GFP Abcam (ab290) and
mouse antibody to a-tubulin (Sigma: B512), rabbit antibody to phospho-Thr183/
Tyr185 SAPK/JNK (Cell Signalling: 9251) and SAPK/JNK (Cell Signalling: 9252),
rabbit anti-b-catenin antibody (Santa Cruz Biotechnology: H102), mouse antibody
to glyceraldehyde-3-phosphate dehydrogenase (Abcam: ab9484), mouse
monoclonal ubiquitin antibody (Life Sensors: FK2 AB120) and secondary
antibodies coupled to horseradish peroxidase (Jackson Immunoresearch). Alexa
Fluor-conjugated antibodies were purchased from Molecular Probes, Invitrogen.
Antibodies were used according to the recommendations of the manufacturers or
associated references.
Western blots and immunoprecipitation and GST pulldown assays. For
western blots, conditions are indicated as shown above the gels. Cells were serum-
starved for 24 h and either treated with the indicated inhibitors or controls,
followed by stimulation with fetal calf serum or human recombinant Wnt5a
(RD systems, 645-WN-010) for the indicated times. Protein extracts were separated
using SDS–PAGE and probed as stated in the figures. For immunoprecipitation,
after pre-clearing with agarose beads and incubation with antibodies, protein
G-agarose beads were added to the lysates and bound immune complexes were
recovered, washed three times in lysis buffer and separated on SDS–PAGE for
western blot analysis56. GST pulldown assays were carried out as previously
described. Full blots are provided for main and Supplementary Figures are
provided in the Supplementary Data File.
Cell migration assays. Cell migration was evaluated using 8-mm pore
polycarbonate membrane transwell chambers (Corning Costar). The bottom
side of the membrane was coated with 25 mg ml 1 rat-tail collagen I. Cells were
serum-starved for 16 h and then plated in the top chamber. Medium with or
without 10% fetal calf serum was added to the bottom chamber and cells
were incubated for 12 h. Non-migrated cells were scraped from the top of the
membrane. Migrated cells were fixed in 4% formaldehyde and stained with 0.1%
crystal violet for counting. Alternatively, cells on the inserts were trypsinized and
assessed by using the CellTiter-Glo Luminescent Cell Viability Assay as described
by the manufacturer (Promega Corporation).
Cell proliferation assays. Unless otherwise specified, all cell proliferation
experiments used CellTiter-Glo Luminescent Cell Viability Assay. After plating
cells on 96-well plates (3610, Corning Costar) in 100 ml media per well, cell
proliferation activity was assessed at different times using the CellTiter-Glo
Luminescent Cell Viability Assay as described by the manufacturer (Promega
Corporation). Values are means and s.d. of three independent experiments.
Measure of anchorage-independent cell proliferation. Anchorage-independent
growth was measured in 96-well plates. The 6% agarose solution stock was diluted
in SUM149 culture medium and 100 ml was used to make the 0.6% bottom layer in
opaque with clear bottom 96-well assay plates. After the bottom layer was gelified, a
serial twofold dilution of cells was mixed with complete culture media containing
agarose at a final concentration of 0.3%. Fifty microlitres per well (corresponding to
250 and 500 cells) were added to the bottom layer. Cells were incubated for 21 days
at 37 C in 5% CO2 atmosphere. Unless otherwise stated, cell number was
quantified using CellTiter-Glo reagent (Promega) as follows: 75 ml of CellTiter-Glo
reagent (Promega) and luminescence was recorded after 10 min of incubation time
using a microplate luminometer.
Mass spectrometry analyses. Mass spectrometry analyses were carried out with
LC-MS/MS using a LTQ-Velos-Orbitrap (Thermo Electron, Bremen, Germany)
connected to a nanoLC Ultimate 3000 Rapid Separation Liquid chromatography
system (Dionex, Sunnyvale, CA, USA). Five microlitres of peptide sample corre-
sponding to one-sixth of the whole sample were injected for each analysis. After
preconcentration and washing of the sample on a Dionex Acclaim PepMap100 C18
column (2 cm, 100mm internal diameter (i.d.), 100A, 5 mm particle size), peptides
were separated on a Dionex Acclaim PepMap RSLC C18 column (15 cm, 75 mm
i.d., 100A, 2 mm particle size; Dionex, Amsterdam) at a flow rate of 300 nl min 1
using a two-step linear gradient (4–20% acetonitrile/H2O; 0.1% formic acid) for
90 min and 20–45% acetonitrile/H2O; 0.1% formic acid for 30 min. Separation of
the peptides was monitored by a ultraviolet detector (absorption at 214 nm). The
nanoLC was coupled to a nanospray source of a linear ion trap Orbitrap mass
spectrometer (LTQ OrbitrapVelos, Thermo Electron). The linear trap quadrupole
(LTQ) spray voltage was 1.4 kV and the capillary temperature was set at 275 C. All
samples were measured in a data-dependent acquisition mode. Each run was
preceded by a blank MS run to monitor system background. The peptide masses
are measured in a survey full scan (scan range 300–1,700 m/z, with 30 K full-width
at half-maximum resolution at m/z¼ 400, target AGC value of 1 106 and max-
imum injection time of 200 ms). In parallel to the high-resolution full scan in the
Orbitrap, the data-dependent CID scans of the 10 most intense precursor ions were
fragmented and measured in the linear ion trap (normalized collision energy of
35%, activation time of 10 ms, target AGC value of 1 104, maximum injection
time of 100 ms and isolation window of 2 Da). The fragment ion masses are
measured in the linear ion trap to have a maximum sensitivity and the maximum
amount of MS/MS data. Dynamic exclusion was implemented with a repeat count
of 1 and exclusion duration of 30 s.
Raw files generated from mass spectrometry analysis were processed with
Proteome Discoverer 1.4 (Thermo Fisher Scientific). This software was used to
search data via in-house Mascot server (version 2.2.03; Matrix Science Inc.,
London, UK) against the Human database subset (20,247 references) of the
Swissprot 02 database. For the database search, the following settings were used: a
maximum of one miscleavage, oxidation as a variable modification of methionine,
carbamidomethylation as a fixed modification of cysteine and trypsin was set as the
enzyme. A peptide mass tolerance of 6 p.p.m. and a fragment mass tolerance of
0.8 Da was used for search analysis. Only peptides with high stringency identity
Mascot score (false discovery rate (FDR)o1%) were used for protein identification.
For each immunoprecipitation experiment, three conditions were used to select
specific protein complexes from experimental contaminants: positive
immunoprecipitation with 2G4 anti-VANGL2 antibody or control beads alone or
coupled to control isotypic antibody.
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Electron microscopy. Cells were fixed with 4% formaldehyde and 0.1%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2), scraped and pelleted in 12%
gelatin and infused with 2.3 M sucrose before mounting and freezing in lN2.
Sections were cut at  110 C, picked up with a 50:50 mixture of 2.3 M sucrose
and 2% methyl cellulose and transferred on formvar/carbon-coated grids. Single
labelling was performed with rat anti-VANGL2 and mouse-anti-p62 followed
by secondary bridging antibodies (Sigma) and 10 nm protein A gold (CMC,
Utrecht, the Netherlands). Double labelling against VANGL2 (1/50 antibody
dilution) and p62 (1/300 antibody dilution) was performed sequentially with 0.1%
glutaraldehyde as blocking step. Sections were observed at 80 kV in a JEOL-JEM
1230, micrographs recorded with a Morada charge-coupled device camera
(SIS, Germany) and processed with the Photoshop software (Adobe).
References
1. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish
tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98,
10869–10874 (2001).
2. Bertucci, F., Finetti, P. & Birnbaum, D. Basal breast cancer: a complex and
deadly molecular subtype. Curr. Mol. Med. 12, 96–110 (2012).
3. Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in
cancer. Nat. Rev. Cancer 13, 11–26 (2013).
4. Lin, S. Y. et al. Beta-catenin, a novel prognostic marker for breast cancer: its
roles in cyclin D1 expression and cancer progression. Proc. Natl Acad. Sci. USA
97, 4262–4266 (2000).
5. Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U. & Borresen-Dale, A. L.
E-cadherin and alpha-, beta-, and gamma-catenin protein expression in
relation to metastasis in human breast carcinoma. J. Pathol. 185, 262–266
(1998).
6. Khramtsov, A. I. et al. Wnt/beta-catenin pathway activation is enriched in
basal-like breast cancers and predicts poor outcome. Am. J. Pathol. 176,
2911–2920 (2010).
7. Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP
signaling in breast cancer cell migration. Cell 151, 1542–1556 (2012).
8. Anastas, J. N. et al. A protein complex of SCRIB, NOS1AP and VANGL1
regulates cell polarity and migration, and is associated with breast cancer
progression. Oncogene 31, 3696–3708 (2011).
9. Gujral, T. S. et al. A noncanonical frizzled2 pathway regulates epithelial-
mesenchymal transition and metastasis. Cell 159, 844–856 (2014).
10. Simons, M. & Mlodzik, M. Planar cell polarity signaling: from fly development
to human disease. Annu. Rev. Genet. 42, 517–540 (2008).
11. Sebbagh, M. & Borg, J. P. Insight into planar cell polarity. Exp. Cell Res. 328,
284–295 (2014).
12. Lei, Y. P. et al. VANGL2 mutations in human cranial neural-tube defects.
N. Engl. J. Med. 362, 2232–2235 (2010).
13. Tournier, C. The 2 faces of JNK signaling in cancer. Genes Cancer 4, 397–400
(2013).
14. Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter
proteins. Autophagy 7, 279–296 (2010).
15. Bertrand, M. et al. SQSTM1/p62 regulates the expression of junctional proteins
through epithelial-mesenchymal transition factors. Cell Cycle 14, 364–374 (2015).
16. Moscat, J. & Diaz-Meco, M. T. p62 at the crossroads of autophagy, apoptosis,
and cancer. Cell 137, 1001–1004 (2009).
17. Rolland, P. et al. The ubiquitin-binding protein p62 is expressed in breast
cancers showing features of aggressive disease. Endocr. Relat. Cancer 14, 73–80
(2007).
18. Duran, A. et al. The signaling adaptor p62 is an important NF-kappaB
mediator in tumorigenesis. Cancer Cell 13, 343–354 (2008).
19. Luo, R. Z. et al. Accumulation of p62 is associated with poor prognosis in
patients with triple-negative breast cancer. Onco. Targets Ther. 6, 883–888
(2013).
20. Wei, H., Wang, C., Croce, C. M. & Guan, J. L. p62/SQSTM1 synergizes with
autophagy for tumor growth in vivo. Genes Dev. 28, 1204–1216 (2014).
21. Belotti, E. et al. Molecular characterisation of endogenous Vangl2/Vangl1
heteromeric protein complexes. PLoS ONE 7, e46213 (2012).
22. Charafe-Jauffret, E. et al. Gene expression profiling of breast cell lines identifies
potential new basal markers. Oncogene 25, 2273–2284 (2006).
23. Belotti, E. et al. The human PDZome: a gateway to PDZ mediated functions.
Mol. Cell Proteomics 12, 2587–2603 (2013).
24. McCaffrey, L. M., Montalbano, J., Mihai, C. & Macara, I. G. Loss of the Par3
polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 22,
601–614 (2012).
25. Pankiv, S. et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate
degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem.
282, 24131–24145 (2007).
26. Park, M. & Moon, R. T. The planar cell-polarity gene stbm regulates cell
behaviour and cell fate in vertebrate embryos. Nat. Cell Biol. 4, 20–25 (2002).
27. Lamark, T. et al. Interaction codes within the family of mammalian Phox and
Bem1p domain-containing proteins. J. Biol. Chem. 278, 34568–34581 (2003).
28. Giese, A. P. et al. Gipc1 has a dual role in Vangl2 trafficking and hair bundle
integrity in the inner ear. Development 139, 3775–3785 (2012).
29. Sanchez, P., De Carcer, G., Sandoval, I. V., Moscat, J. & Diaz-Meco, M. T.
Localization of atypical protein kinase C isoforms into lysosome-targeted
endosomes through interaction with p62. Mol. Cell Biol. 18, 3069–3080 (1998).
30. Gravel, M., Iliescu, A., Horth, C., Apuzzo, S. & Gros, P. Molecular and cellular
mechanisms underlying neural tube defects in the loop-tail mutant mouse.
Biochemistry 49, 3445–3455 (2010).
31. Darken, R. S. et al. The planar polarity gene strabismus regulates convergent
extension movements in Xenopus. EMBO J. 21, 976–985 (2002).
32. Unterseher, F. et al. Paraxial protocadherin coordinates cell polarity during
convergent extension via Rho A and JNK. EMBO J. 23, 3259–3269 (2004).
33. Schambony, A. & Wedlich, D. Wnt-5A/Ror2 regulate expression of XPAPC
through an alternative noncanonical signaling pathway. Dev. Cell 12, 779–792
(2007).
34. Charafe-Jauffret, E. et al. ALDH1-positive cancer stem cells predict engraftment
of primary breast tumors and are governed by a common stem cell program.
Cancer Res. 73, 7290–7300 (2013).
35. Hatakeyama, J., Wald, J. H., Printsev, I., Ho, H. Y. & Carraway, 3rd K. L.
Vangl1 and Vangl2: planar cell polarity components with a developing role in
cancer. Endocr. Relat. Cancer 21, R345–R356 (2014).
36. Kaucka, M. et al. The planar cell polarity pathway drives pathogenesis of
chronic lymphocytic leukemia by the regulation of B-lymphocyte migration.
Cancer Res. 73, 1491–1501 (2013).
37. Archibald, A., Mihai, C., Macara, I. G. & McCaffrey, L. Oncogenic suppression
of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of
Par3. Oncogene 34, 3199–3206 (2014).
38. Lindqvist, M. et al. Vang-like protein 2 and Rac1 interact to regulate adherens
junctions. J. Cell Sci. 123, 472–483 (2010).
39. Whitmarsh, A. J. The JIP family of MAPK scaffold proteins. Biochem. Soc.
Trans. 34, 828–832 (2006).
40. Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell 147, 759–772 (2011).
41. Wu, J. & Mlodzik, M. The frizzled extracellular domain is a ligand for Van
Gogh/Stbm during nonautonomous planar cell polarity signaling. Dev. Cell 15,
462–469 (2008).
42. Devenport, D. & Fuchs, E. Planar polarization in embryonic epidermis
orchestrates global asymmetric morphogenesis of hair follicles. Nat. Cell Biol.
10, 1257–1268 (2008).
43. Parameswaran, N., Enyindah-Asonye, G., Bagheri, N., Shah, N. B. & Gupta, N.
Spatial coupling of JNK activation to the B cell antigen receptor by tyrosine-
phosphorylated ezrin. J. Immunol. 190, 2017–2026 (2013).
44. Duran, A. et al. p62 is a key regulator of nutrient sensing in the mTORC1
pathway. Mol. Cell 44, 134–146 (2011).
45. Bubici, C. & Papa, S. JNK signalling in cancer: in need of new, smarter
therapeutic targets. Br. J. Pharmacol. 171, 24–37 (2014).
46. Yunokawa, M. et al. Efficacy of everolimus, a novel mTOR inhibitor, against
basal-like triple-negative breast cancer cells. Cancer Sci. 103, 1665–1671 (2012).
47. Singh, J. et al. Phase 2 trial of everolimus and carboplatin combination in
patients with triple negative metastatic breast cancer. Breast Cancer Res. 16,
R32 (2014).
48. Wang, Z. et al. Blocking autophagy enhanced cytotoxicity induced by
recombinant human arginase in triple-negative breast cancer cells. Cell Death
Dis. 5, e1563 (2014).
49. Luxardi, G., Marchal, L., Thome, V. & Kodjabachian, L. Distinct Xenopus
Nodal ligands sequentially induce mesendoderm and control gastrulation
movements in parallel to the Wnt/PCP pathway. Development 137, 417–426
(2010).
50. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
51. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic
subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
52. Sabatier, R. et al. Down-regulation of ECRG4, a candidate tumor suppressor
gene, in human breast cancer. PLoS ONE 6, e27656 (2011).
53. Adelaide, J. et al. Integrated profiling of basal and luminal breast cancers.
Cancer Res. 67, 11565–11575 (2007).
54. McShane, L. M. et al. REporting recommendations for tumor MARKer
prognostic studies (REMARK). Breast Cancer Res. Treat. 100, 229–235 (2006).
55. Qin, Y., Capaldo, C., Gumbiner, B. M. & Macara, I. G. The mammalian Scribble
polarity protein regulates epithelial cell adhesion and migration through
E-cadherin. J. Cell Biol. 171, 1061–1071 (2005).
56. Audebert, S. et al. Mammalian Scribble forms a tight complex with the betaPIX
exchange factor. Curr. Biol. 14, 987–995 (2004).
Acknowledgements
We thank Francine Cheillan for her technical support, Nelson Dusetti and Juan Iovanna
for advice, Emilie Baudelet and Luc Camoin for protein sample handling and mass
spectrometry data analysis, Avais M. Daulat for the production of lentiviruses, Mireille
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10318
14 NATURE COMMUNICATIONS | 7:10318 | DOI: 10.1038/ncomms10318 | www.nature.com/naturecommunications
Montcouquiol for the GFP–VANGL2 construct, members of the TrGET and CRCM
animal facilities for their technical assistance with NSG mice, Vincent Géli, Pascale
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